Drugs / CD70.CAR NK Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07164469 | Dec 2026 → Sep 2031 expected | Hodgkins lymphoma, large B-cell lymphoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD70.CAR NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07164469 ↗ |
| Modality | Cell therapy | “CB-derived CD70.CAR NK cell therapy” NCT07164469 ↗ |
| Route | Intravenous | “Given by IV Infusion” NCT07164469 ↗ |
| Target | CD70 | “CD70.CAR NK cells” NCT07164469 ↗ |